tiprankstipranks
Kiniksa Pharmaceuticals (KNSA)
NASDAQ:KNSA
US Market

Kiniksa Pharmaceuticals Stock Analysis & Ratings

KNSA Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$7.36 - $16.68
Previous Close$9.88
Volume112.66K
Average Volume (3M)313.17K
Market CapN/A
Enterprise ValueN/A
P/E Ratio-5.1
Beta-0.04
Next EarningsAug 03, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score4


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

KNSA FAQ

What was Kiniksa Pharmaceuticals’s price range in the past 12 months?
Kiniksa Pharmaceuticals lowest stock price was $7.36 and its highest was $16.68 in the past 12 months.
    What is Kiniksa Pharmaceuticals’s market cap?
    Currently, no data Available
    What is Kiniksa Pharmaceuticals’s price target?
    The average price target for Kiniksa Pharmaceuticals is $19.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is $22.00 ,the lowest forecast is $16.00. The average price target represents 92.31% Increase from the current price of $9.88.
      What do analysts say about Kiniksa Pharmaceuticals?
      Kiniksa Pharmaceuticals’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
        When is Kiniksa Pharmaceuticals’s upcoming earnings report date?
        Kiniksa Pharmaceuticals’s upcoming earnings report date is Aug 03, 2022 which is in 34 days.
          How were Kiniksa Pharmaceuticals’s earnings last quarter?
          Kiniksa Pharmaceuticals released its earnings results on May 03, 2022. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.43 by $0.07.
            Is Kiniksa Pharmaceuticals overvalued?
            According to Wall Street analysts Kiniksa Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
              Does Kiniksa Pharmaceuticals pay dividends?
              Kiniksa Pharmaceuticals does not currently pay dividends.
              What is Kiniksa Pharmaceuticals’s EPS estimate?
              Kiniksa Pharmaceuticals’s EPS estimate is -$0.43.
                How many shares outstanding does Kiniksa Pharmaceuticals have?
                Kiniksa Pharmaceuticals has 34,275,047 shares outstanding.
                  What happened to Kiniksa Pharmaceuticals’s price movement after its last earnings report?
                  Kiniksa Pharmaceuticals reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.43. Following the earnings report the stock price went up 7.439%.
                    Which hedge fund is a major shareholder of Kiniksa Pharmaceuticals?
                    Among the largest hedge funds holding Kiniksa Pharmaceuticals’s share is Consonance Capital. It holds Kiniksa Pharmaceuticals’s shares valued at N/A.

                      ---

                      Kiniksa Pharmaceuticals Stock Analysis

                      The Kiniksa Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Kiniksa Pharmaceuticals

                      Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason, and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Magenta Therapeutics
                      Avrobio
                      Tricida
                      Scholar Rock Holding

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis